Antibodies are indispensable reagents for most biomedical experiments, allowing researchers to identify and react with target proteins. However, discrepancies in the results of an experiment can be caused by non-specific antibody binding or batch-to-batch variations in the antibodies used. These issues can be overcome by using recombinant antibodies.

Role of Custom Antibodies in Neurological Disorders (rAbs) are produced in vitro with synthetic genes, reducing the need for animal immunization, and they can be manufactured at scale, increasing lot-to-lot consistency. This means that recombinant antibodies provide more consistent and reliable results for your experiments. Recombinant antibodies are also highly versatile and can be created as full-length monoclonal antibodies, Fab fragments, scFvs, bispecific antibodies and antibody fusion proteins.

Custom Rabbit Monoclonal Antibody Production: Why Researchers Prefer Rabbit mAbs

In addition, recombinant antibodies can be modified to improve their affinity and specificity. This can be achieved through antibody engineering which allows scientists to modify a variable chain of an existing antibody or create an entirely new one. This can increase the sensitivity of an immunoassay, enable broader targeting, and improve the signal to noise ratio.

Advanced recombinant antibodies are now used in clinical trials for the treatment of various viral diseases including AIDS and parasitic diseases such as malaria. These recombinant antibodies have replaced polyclonal antibodies which were previously used in the trials, due to their ability to bind more efficiently and with greater specificity to target epitopes.